Why the study?
What is the role of clinically relevant biomarkers in predicting rhythm outcomes after catheter ablation for atrial fibrillation?
What is the role of clinically relevant biomarkers in predicting rhythm outcomes after catheter ablation for atrial fibrillation?
Clinically relevant biomarkers, particularly blood-based markers reflecting underlying pathophysiological mechanisms, may play an important role in predicting rhythm outcomes after atrial fibrillation ablation.
No data on biomarkers; leaves open their role in predicting rhythm outcomes after AF ablation.
Atrial fibrillation (AF) occurs as the result of numerous complex physiological processes in the atria leading to AF promotion and maintenance. Improved diagnostic techniques have identified various biomarkers which may play an important role in the prediction of AF related outcomes (cardio- and cerebrovascular events, as well as mortality and rhythm outcomes). Biomarkers refer to 'biological markers' and biomarkers in blood, urine as well as imaging marker (eg, dimensions (left atrial diameter and volume), anatomical features (left appendage and pulmonary vein anatomy), and physiological pattern (LAA flow velocity)) may play important role(s) as clinically important indices in relation to outcomes after different therapeutic strategies. However, the main domain in the biomarker field has focused on blood-based biomarkers, which are widely used to predict therapeutic success regarding underlying pathophysiological mechanism, such as inflammation, fibrosis, endothelial damage. This review provides an update of the role of clinically relevant biomarkers in AF, with particular focus on AF rhythm outcomes.
No takes yet. Share an insight, caveat, or question.
Kornej et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: